

# Recombinant Human TACSTD2/TROP2 protein (rFc Tag)

Catalog Number: Eg3329

## Basic Information

**Species:**  
Human**Purity:**  
>90 %, SDS-PAGE**Tag:**  
rFc Tag

## Technical Specifications

**Purity:**

&gt;90 %, SDS-PAGE

**Endotoxin Level:**

&lt;0.1 EU/ µg protein, LAL method

**Source:**

HEK293-derived Human TACSTD2 protein His27-Thr274 (Accession# P09758) with a rabbit IgG Fc tag at the C-terminus.

**GeneID:**

4070

**Accession:**

P09758

**Predicted Molecular Mass:**

54.2 kDa

**SDS-PAGE:**

55-70 kDa, reducing (R) conditions

**Formulation:**

Lyophilized from 0.22 µm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.

## Biological Activity

Not tested

## Storage and Shipping

**Storage:**

It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.

- Until expiry date, -20°C to -80°C as lyophilized proteins.
- 3 months, -20°C to -80°C under sterile conditions after reconstitution.

**Shipping:**

The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

## Reconstitution

Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.

## Background

TACSTD2 encodes a transmembrane glycoprotein Trop2, that is overexpressed in most carcinomas where it has been associated with cancer cell plasticity, tumor growth, metastasis and prognosis. In humans, congenital mutations of TACSTD2 cause a gelatinous drop-like corneal disease (GDLD), a rare autosomal recessive disease characterized by the development of bilateral corneal amyloidosis and eventually blindness. Overexpression of TROP2/TACSTD2 has been shown to confer a poor prognosis, notably among patients with gynecologic or gastrointestinal tumors. TROP2/TACSTD2 has also been shown to have some impact on the tumor immune microenvironment and may modulate immunotherapy response. In cervical cancer, TROP2 levels were associated with increased intratumoral tumor-infiltrating lymphocytes and programmed cell death-ligand 1 (PD-L1) expression. Conversely, TROP2/TACSTD2-high tumors had lower gene expression of immune cell markers in breast and non-small cell lung cancer and were independently associated with poor response to immune checkpoint inhibitors (ICIs).


## References

- 1.Lenárt, Sára. et al. (2022) Sci Rep. 12(1):9583.
- 2.Morgenstern-Kaplan, Dan. et al. (2024) Oncologist. 29(11):e1480-e1491.
- 3.Abbas, Mahmoud. et al. (2023) Oncol Lett. 26(6):527.

## Synonyms

TACSTD2, Cell surface glycoprotein Trop-2, EGP 1, GA733, GA733 1

## Selected Validation Data



Purity of Recombinant Human TACSTD2 was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) and non-reducing (NR) conditions and stained using Coomassie blue.

For technical support and original validation data for this product please contact

T: 027-87531629

E: [Proteintech-CN@ptglab.com](mailto:Proteintech-CN@ptglab.com)

W: [ptgcn.com](http://ptgcn.com)

This product is exclusively available under Proteintech Group brand and is not available to purchase from any other manufacturer.